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ABSTRACT: PRPF8-retinitis pigmentosa is said to be severe but there has been no overview of 
phenotype across different mutations.  We screened RP patients for PRPF8 mutations and 
identified three new missense mutations, including the first documented mutation outside exon 42 
and the first de novo mutation. This brings the known RP-causing mutations in PRPF8 to nineteen. 
We then collated clinical data from new and published cases to determine an accurate prognosis for 
PRPF8-RP. Clinical data for 75 PRPF8-RP patients were compared, revealing that while the effect 
on peripheral retinal function is severe, patients generally retain good visual acuity in at least one 
eye until the fifth or sixth decade. We also noted that prognosis for PRPF8-RP differs with 
different mutations, with p.H2309P or p.H2309R having a worse prognosis than p.R2310K. This 
correlates with the observed difference in growth defect severity in yeast lines carrying the 
equivalent mutations, though such correlation remains tentative given the limited number of 
mutations for which information is available. The yeast phenotype is caused by lack of mature 
spliceosomes in the nucleus, leading to reduced RNA splicing function. Correlation between yeast 
and human phenotypes suggests that splicing factor RP may also result from an underlying splicing 
deficit.  ©2010 Wiley-Liss, Inc. 
KEY WORDS: Retinitis pigmentosa, PRPF8, mRNA splicing, adRP 
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INTRODUCTION 
Retinitis Pigmentosa (RP) is a progressive rod-cone dystrophy leading to night-blindness, loss of peripheral 
visual fields and a reduced or absent electroretinogram (ERG), with later variable loss of central retinal function. It 
is an inherited disease primarily affecting the rod photoreceptors and the retinal pigment epithelium, and is the 
commonest inherited retinal dystrophy, affecting approximately 1 in 3500 people worldwide (Bunker, et al., 1984). 
Clinical manifestations include bone-spicule pigmentation in the retinal mid-periphery, arteriolar attenuation and 
waxy optic disc pallor. 
 RP is clinically and genetically heterogeneous, with all modes of Mendelian inheritance found in families 
with the condition.  To date some forty-six loci have been identified for non-syndromic RP, and for these thirty six 
of the causative genes have been identified (see www.sph.uth.tmc.edu/RetNet/disease.htm for full list). These 
include genes encoding components of the phototransduction cascade and the visual cycle by which the 
chromophore component of rhodopsin is recycled, retinal transcription factors, photoreceptor structural proteins 
and cilia proteins, the latter being components of the highly evolved ciliary structure of the photoreceptor outer 
segments (Hims, et al., 2003; Roepman and Wolfrum, 2007). In addition, in a somewhat perplexing discovery, 
mutations in four ubiquitously expressed splicing factors, pre-mRNA processing factor 8 (PRPF8 (MIM# 607300, 
McKie, et al., 2001), PRPF31 (MIM# 606419, Vithana, et al., 2001), PRPF3 (MIM# 607301, Chakarova, et al., 
2002) and PAP1 (MIM# 607331, Keen, et al., 2002; Maita, et al., 2004) were also found in dominant RP patients 
(reviewed by Mordes, et al., 2006).  In total mutations in splicing factors are thought to be the second most 
common cause of autosomal dominant RP (Sullivan, et al., 2006). 
PRPF8 is one of the largest and most highly conserved proteins found in the nucleus and is essential for pre-
mRNA splicing (reviewed by Grainger and Beggs, 2005). It has remarkably low sequence similarity to other 
proteins, making it difficult to predict function from structure, though some domain structure has been determined 
(Boon, et al., 2006). It is a component of the U5 snRNP and U5.U4/U6 tri-snRNP (Boon, et al., 2007; Stevens and 
Abelson, 1999) and may function as a large protein scaffold in the spliceosome (Turner, et al., 2006, for review see 
Grainger and Beggs, 2005). In addition, recent crystal structures of C-terminal domains suggest a possible role in 
the catalysis of splicing (Abelson, 2008). Unlike other known splicing factors, as a component of the U5 snRNPs, 
PRPF8 participates in both U2 and U12 splicing (Luo, et al., 1999). 
The PRPF8 gene is located on the short arm of chromosome 17 and encodes 42 exons spanning ~36kb of 
genomic sequence.  It is highly conserved in both sequence and size, which varies between 220 and 280kDa in 
different organisms (Hodges, et al., 1995; Luo, et al., 1999). Sixteen different PRPF8 mutations, including 
missense, premature stop and deletions have been identified to date (De Erkenez AC, 2002; Kondo, et al., 2003; 
Martinez-Gimeno, et al., 2003; McKie, et al., 2001; Ziviello, et al., 2005), all but one of which cluster in a highly 
conserved region within the last exon. These mutations account for approximately 3% of dominant RP or around 
1% of all RP cases (Sullivan, et al., 2006). Real-time PCR analysis has shown similar expression of both wild type 
and mutant alleles in cell lines from RP patients carrying a nonsense mutation (Gamundi, et al., 2008). This 
suggests that this transcript (and by inference other mutant transcripts) is not removed by nonsense mediated 
decay.  This contrasts with the likely mechanism for mutations in PRPF31, for which evidence strongly suggests 
haploinsufficiency (Abu-Safieh, et al., 2006).   
Mutations in PRPF8 have been described as causing a severe form of dominant RP (Gamundi, et al., 2008; 
Tarttelin, et al., 1996; Walia, et al., 2008).  However, in contrast to the phenotype for the commoner PRPF31 form 
of splicing-factor RP, which has been well documented in patients with a variety of mutations (Al-Maghtheh, et 
al., 1996; Evans, et al., 1995) there has been no published overview of PRPF8-RP phenotype across a range of 
mutations. Patients and clinicians would value such an analysis since it could help provide a more accurate 
prognosis. Here we report three new PRPF8 mutations, including one outside exon 42, and a de-novo case of a 
known mutation; review all published PRPF8 mutations; present clinical data on the new cases and additional 
clinical data on two published PRPF8-RP families; and review the published clinical observations in eight further 
PRPF8 families, in order to gain a clearer picture of this form of RP. The severity of retinal degeneration observed 
in patients with the three most common PRPF8 mutations correlates with the severity of the temperature-sensitive 
growth phenotype found in haploid yeast (Sacchromyces cerivisia) strains carrying the equivalent mutations. As 
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the mechanism underlying the yeast phenotype is known, this correlation between yeast and human phenotypes 
implies that a similar defect may underlie the human condition.  
 
MATERIALS AND METHODS 
Patients and Control subjects 
Data presented in Table 1 include new clinical information on two families for which phenotypes were 
published previously only as brief summaries in the genetics literature (identified in Table 1 as British1 (McKie, et 
al., 2001; Tarttelin, et al., 1996) and South African (Greenberg, et al., 1994; McKie, et al., 2001)). In addition, 
published clinical information from eight families are summarised (identified in Table 1 as Dutch (van Lith-
Verhoeven, et al., 2002) Japanese (Kondo, et al., 2003), Spanish1-4 (Martinez-Gimeno, et al., 2003), US1 (Walia, 
et al., 2008) and US2 (Kojis, et al., 1996). Lastly, clinical information is given for the de novo case (British2) and 
three new families (British 3, 4 and 5) described herein. No clinical information is available for patients with the 
remaining published mutations.  
Nucleotide numbering in the text and tables reflects cDNA numbering with +1 corresponding to the A of the 
ATG translation initiation codon in the reference sequence (accession number NM_006445.3), according to 
journal guidelines (www.hgvs.org/mutnomen). Mutations are described at the protein level by numbered codons 
based on the same reference sequence, with the initiation codon as codon 1.   
For the new cases, after obtaining informed consent, a full ophthalmic examination was conducted, including 
Goldman perimetry, Optical Coherence Tomography (OCT) and, where possible, photopic and scotopic ERG 
testing. A medical history was also obtained and a sample of peripheral blood taken. Genomic DNA was extracted 
from the blood using the QIAamp DNA Blood Midi Kit (Qiagen, Crawley, United Kingdom) according to the 
manufacturer’s instructions. 
Although the clinical data in Table 1 are incomplete, mean acuity in the better seeing eye was calculated for the 
three most common and the remaining mutations where this information was available. This calculation was made 
by converting Snellen acuity into an ETDRS letter score. Acuities of hand movements and counting fingers were 
assumed to be equivalent to 0 ETDRS letters. The Mann-Whitney U test was used to evaluate the significance of 
apparent differences in age of onset between patients with the H2309P mutation and those with R2310K or 
H2309R, since the H2309P data are not normally distributed. The significance of the difference in age of onset 
between patients with R2310K and patients with H2309R was tested by the t test since the values of these samples 
were normally distributed. 
 
Microsatellite analysis to confirm paternity for the de novo mutation case 
Aliquots of DNA from affected and unaffected family members were genotyped for seven different 
microsatellite markers on three different chromosomes. The products were mixed with the size standard GeneScan 
500-ROX (Applied Biosystems, Warrington, United Kingdom) and resolved by electrophoresis on a 3130xl 
Genetic Analyser (Applied Biosystems). The results were analysed using the GeneMapper version 4.0 software 
(Applied Biosystems).  
 
DNA sequencing 
Specific primer pairs were selected encompassing all exons of PRPF8 (Table 2). These were utilised in the PCR 
to amplify products which were initially digested with ExoSAP-IT (GE Healthcare, Chalfont St. Giles, United 
Kingdom) according to the supplier’s instructions. The digested DNA was sequenced directly using the BigDye 
Terminator version 3.1 Cycle Sequencing Kit and the 3130xl Genetic Analyser according to the manufacturer’s 
instructions (Applied Biosystems). 
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RESULTS 
Clinical and genetic analysis of new cases 
Table 3 summarises all PRPF8 RP causing mutations known to date. Most have been reported elsewhere but we 
report three novel mutations, S2118F, R2310S and Y2334N.  
Y2334N was identified in a Caucasian father and son diagnosed with dominant RP at Moorfields Eye Hospital. 
The father was referred by his GP while the son, who accompanied his father, was unaware of symptoms on the 
first visit.  Subsequently that grandfather was seen aged 67 years.  He reported symptoms from late teens but 
maintained central macular function.  Fundus photography and autofluorescence in all three generations revealed a 
typical RP fundal appearance with bone-spicule pigmentation in the mid periphery and extensive retinal pigment 
epithelial atrophy (Figs 1a-c and Fig 2).  OCT analysis revealed cystoid macular oedema (CMO) in the son.  
R2310S was identified in a single patient with RP seen at Moorfields eye hospital. The patient gave a family 
history consistent with dominant inheritance but no further family members were examined. He was first aware of 
symptoms in his late teens and had severely constricted visual fields on examination age 35. Ophthalmic 
examination revealed bone-spicule pigmentation and RPE atrophy.  
The S2118F mutation was identified in a large family segregating RP in a dominant fashion. Linkage analysis 
implicated a mutation in the PRPF8 gene but screening of PRPF8 exon 42 failed to reveal a mutation. It was then 
decided to sequence additional 3’ exons, leading to the identification of the S2118F missense change in exon 38. 
Only clinical details for the proband were available for this study. Examination of this 57 year old male revealed 
extensive bone-spicule pigmentation, cataracts and constricted visual fields.  
Each of these mutations change amino-acids conserved in all eukaryotes. The substitutions involved are non-
conservative, giving negative scores on the Blosum62 matrix. These mutations were excluded from over 120 
ethnically matched Caucasian control DNAs and Y2334N was also shown to segregate with RP in the family. 
These mutations are therefore highly likely to be the cause of RP in these families and cases, as defined by the 
criteria used by Stone 2003 (Stone, 2003). 
We also identified a case with a de novo missense mutation.  This 9-year-old Caucasian boy was a tertiary 
referral to the eye department, St James’s hospital, Leeds, to investigate symptoms of night blindness. On 
ophthalmic examination RP was diagnosed, but both parents showed normal visual acuity, fundi and visual fields 
to confrontation.  DNA was obtained and screened for known exonic hotspots for retinal degeneration causing 
mutations. This identified the known H2309P mutation in PRPF8. However, on testing, this change was found to 
be absent from both parents. Paternal status was confirmed by genotyping seven microsatellite markers on three 
different chromosomes in the boy and both parents (data not shown). This confirmed that RP in this patient was 
the result of a de novo mutation event.  Fundus photography in the patient revealed a typical RP fundal appearance 
with bone-spicule pigmentation in the mid periphery (Fig 1d). OCT analysis showed CMO in both eyes, with a 
central retinal thickness in the right eye of 591 microns and an indistinct photoreceptor layer (Fig 3).  
 
Genotype-Phenotype analysis 
The data presented in Table 1 are derived from fourteen families with various PRPF8 mutations. In all, clinical 
and genetic information is presented for 75 PRPF8 RP patients, together with a limited overview of phenotype for 
one further family. The clinical information available for each case is often incomplete, since the clinical notes 
and/or published descriptions varied widely in the detail available. Nevertheless, data were available in most cases 
on two key clinical indicators, age at onset of night blindness or visual field loss and visual acuity at age of 
examination, and these have allowed a number of observations to be made.  
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Table 1. Summary clinical data for individuals from published PRPF8-RP families and for the three new families and the de novo case.  
 
Legend: NR= non-recordable; VA= visual acuity; CMO= central macular oedema; CF= counting fingers; HM= hand movements; PSCLO= posterior subcapsular lens opacity; 
PSCC= posterior subcapsular cortical cataract.   References; Dutch family (van Lith-Verhoeven, et al., 2002), British 1 (McKie, et al., 2001; Tarttelin, et al., 1996), British 2 
(described herein), South African (Greenberg, et al., 1994; McKie, et al., 2001), US1 (Walia, et al., 2008), Japanese (Kondo, et al., 2003), Spanish 1-4 (Martinez-Gimeno, et al., 
2003), British 3, 4 and 5 (described herein) and US2 (Kojis, et al., 1996).  
  
 
Identifier Sex Age @ onset Age @ exam Visual field Origin VA Rt VA Lt ERG  Comments  Mutation Reference 
III-1 f 10 69 10° dutch CF 6/9 NR   R2310K 
van Lith-
Verhoeven, 
et al., 2002 
III-5 m 40 64  temp scotoma dutch 6/7.5 6/19 NR milder phenotype R2310K " 
III-6 f 6 76 10° dutch 6/120 6/7.5 NR   R2310K " 
III-7 m 40 68 10° dutch 6/19 6/9 NR   R2310K " 
III-10 f 16 65 10° dutch 6/30 6/15 NR   R2310K " 
IV-1 m 16 36 10° dutch 6/7.5 6/9 NR   R2310K " 
IV-4 m 35 36 
concentric 
depression dutch 6/7.5 6/9 abnormal   R2310K 
" 
IV-6 f 15 36  ring scotoma dutch 6/15 6/15 NR   R2310K " 
IV-7 m 20 13  ring scotoma dutch 6/4.8 6/4.8 abnormal   R2310K " 
            
FH m 5 38 10° british1 6/18 6/60   
blind @ 30, 
cataract surgery @ 
46  H2309P 
McKie, et al., 
2001; 
Tarttelin, et 
al., 1996 
TH m 5     british1       
registred blind @ 
25 H2309P 
" 
DH f 5 10 5° british1 6/18 6/18   
no change in VA 
in past 10 years H2309P 
" 
LH m >10 14   british1 HM HM   blind at 14 H2309P " 
JH f   37 5° british1 6/36 6/24   PSCLO H2309P " 
DL f 9 24 10° british1 6/12 6/18   CMO H2309P " 
LL f 4 4   british1 6/9 6/9     H2309P " 
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Identifier Sex Age @ onset Age @ exam Visual field Origin VA Rt VA Lt ERG  Comments  Mutation Reference 
NT m 7 11 15° british1 6/24 6/36   CMO H2309P " 
DT f 10 33 5° british1 6/36 6/36   CMO H2309P " 
GFH m 5 72   british1 6/18 6/36   
cataract surgery @ 
66 H2309P 
" 
1014144 f   34 50° british1 6/12 6/9.5     H2309P " 
176571 f   29 40° british1 6/6 6/9 NR   H2309P " 
547129 f 5 64 <10° british1 6/60 6/60   cataract  H2309P " 
1111882 f 24 34 15° british1 6/15 6/15   mild PSCC  H2309P " 
MCEC7507 m 7 7 unknown british1 3/3.8 3/3.8     H2309P " 
De novo 
case m 8 11 10° british2 6/12 6/12 NR CMO H2309P Unpublished 
            
RPD 5.21 m 9 45 constriction south afr CF 6/30   
ON drusen, 
deterioration @ 
30 H2309R 
Greenberg, et 
al., 1994; 
McKie, et al., 
2001 
RPD 5.22 f 13 17   south afr 6/9 6/20 abnormal early cataracts H2309R " 
RPD 5.38 m <10 18   south afr       
cataracts, 
osteogenesis 
imperfecta H2309R 
" 
RPD 5.36 f 15 40   south afr       
vision 
deteriorated in 
mid-40s H2309R 
" 
RPD 5.3 f 15     south afr         H2309R " 
RPD 5.4 m <10 72 constriction south afr CF CF NR 
cataract surgery @ 
65 H2309R 
" 
RPD 5.8 m 7 7   south afr 6/18 6/18     H2309R " 
RPD 5.9 m <10     south afr       early PSCLO H2309R " 
RPD 5.12 f <10     south afr 6/7.5 6/7.5     H2309R " 
RPD 5.16 f       south afr 6/12 6/9     H2309R " 
RPD5.21 m 9     south afr       
deteriorated @ 40, 
optic nerve drusen H2309R 
" 
RPD5.23 m 10     south afr       cataracts H2309R " 
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Identifier Sex Age @ onset Age @ exam Visual field Origin VA Rt VA Lt ERG  Comments  Mutation Reference 
RPD 5.26 f 17     south afr       cataracts H2309R " 
RPD 5.31 m       south afr 6/7.5 6/7.5   cataracts H2309R " 
RPD5.58 f 4 10   south afr 6/12 6/12   
ostogenesis 
imperfecta H2309R 
" 
RPD5.59 m 4   constriction south afr 6/12 6/18     H2309R " 
II:5 f   54   US1 6/60 6/60   CMO H2309R 
Walia, et al., 
2008 
III:6 f   43   US1 6/9 6/9 NR   H2309R " 
III:7 f   44   US1 6/7.5 6/7.5     H2309R " 
III:10 f   28   US1 6/60 6/24   CMO H2309R " 
III:11 f   35   US1 6/9 HM   CMO H2309R " 
III:12 f   26   US1 6/12 6/12 NR CMO H2309R " 
IV:8 m   33   US1 6/12 6/9 NR   H2309R " 
IV:12 m   8   US1 6/7.5 6/7.5     H2309R " 
IV:16 m   14   US1 6/6 6/7.5 NR   H2309R " 
IV:19 f   29   US1 6/60 6/120 NR CMO H2309R " 
IV:20 f   25   US1 CF CF   CMO H2309R " 
IV:21 f   5   US1 6/7.5 6/7.5     H2309R " 
IV:25 m   12   US1 6/7.5 6/7.5     H2309R " 
V:6 m   7   US1 6/12 6/12     H2309R " 
            
II-4 m 10 56 10° japanese 48/60 48/60     E2324fsX2359
Kondo, et al., 
2003 
  m   3   japanese         E2324fsX2359 " 
  f   2   japanese         E2324fsX2359 " 
  m 10 59   japanese HM HM     E2324fsX2359 " 
            
m323 II2 m 20 77 <10° spanish1 6/60 6/60 NR   R2310G 
Martinez-
Gimeno, et 
al., 2003 
m323 III1 m 21 50 10° spanish1 6/48 6/38 NR   R2310G " 
E1368  Towns et al. 
Identifier Sex Age @ onset Age @ exam Visual field Origin VA Rt VA Lt ERG  Comments  Mutation Reference 
m323 IV2 m 7 18 
annular 
scotoma spanish1 6/30 6/30 NR   R2310G " 
           
m618 II1 f 5 45 10° spanish2 6/36 6/36   cataract age 15 L2298fsX2337 " 
m618 III1 f 5 19 30° spanish2 6/12 6/12   cataract age 18 L2298fsX2337 " 
            
v17 II1 f 20 64 10° spanish3 6/60 6/60 NR   L2315fsX2358 " 
v17 III1 m 10 40 10° spanish3 6/38 6/48 NR   L2315fsX2358 " 
v17 III2 m 17 34 10° spanish3 6/7.5 6/6 NR   L2315fsX2358 " 
            
sjd III2 f 10 70   spanish4         V2325fsX2329 " 
sjd III4 m 10 65 10° spanish4 12/60 6/60 NR   V2325fsX2329 " 
sjd IV2 f 10 29 10° spanish4 18/60 24/60 NR   V2325fsX2329 " 
            
MEH-
GC16993 m late teens 67 5° british3 6/18 6/24     Y2334N Unpublished 
MEH-
GC16993 m childhood 48   british3 6/9 6/9   cataract age 50 Y2334N Unpublished 
MEH-
GC16993 m 16 15   british3 6/9 6/9 NR CMO Y2334N Unpublished 
            
MEH-
GC16352 m 18 35 5° british4 6/24 2/60   Cataract age 24 R2310S Unpublished 
           
MEH-
GC171 m Early twenties 57 15° british5 HM 6/18   Cataract age 55 S2118F Unpublished 
            
ucla RP09 family     
severe 
constriction 4 
patients US2     
NR in 4 
patients   E2331fsX2358
Kojis, et al., 
1996 
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Table 2. Primers used to amplify the coding exons of PRPF8 and also including the 5’ non-coding exon 
 
Name Sequence Name Sequence 
r1F1 CGCTGGGAACGCGGAGCGG r6R GAGTGCCTTGGACGTAAAGAAG 
r6F ACACTACCTATGATGTCGACTCT r10R ATGCTTCAGGGCATTCAGCACA 
r9F CAATACAGCCAATGGCATTGCC r16R GTTGTAGTGGGCAGTGTTGGTC 
r16F CGCTGCTGGAAAGCCAACATTC rR20R CACGTCCTGCAGGTTATTGATG 
r19F CATGGATCTGTATAGCCACCTC r23R GTAACCTCATTCTGCAGGTTCC 
r23F GCGGTATTCTGGGACATCAAGA r27R TGTTCTGAGCAATGGCCTCTTG 
r26F CGTTCAGGAATGAGCCATGAAG r32R GTGGTGTAGTCCAGGAACTTG 
r31F TGCCTCCTATAAGTGGAATGTCT r43R AGAGGCCAAACTGCTGAATGTC 
e43F TAGCAGTAGGGATAAGGTGAGG e43R CAGCATCTTGCTGTGAACCGC 
 
Primer numbers include this non-coding exon, so that primers  e43F and e43R in fact amplify what has been referred to in the 
previous literature on this gene as exon 42. 
 
Table 3. Table summarising all known PRPF8 (RP13) RP causing mutations.  
 
PRPF8 nucleotide  change Mutation Type Amino Acid change Reference 
c.6353C>T missense S2118F new 
c.6901C>A missense P2301T (McKie, et al., 2001) 
c.6901C>T missense P2301S (Testa, et al., 2006; Ziviello, et 
al., 2005) 
c.6912C>G missense F2304L (McKie, et al., 2001) 
c.6926A>C       missense H2309P (McKie, et al., 2001) 
c.6926A>G missense H2309R (McKie, et al., 2001) 
c.6928A>G missense R2310G (McKie, et al., 2001) 
c.6929G>A missense R2310K (McKie, et al., 2001) 
c.6930G>C misense R2310S new 
c.6942C>A missense F2314L (McKie, et al., 2001) 
c.6943-6944delC frame-shift L2315fsX2358 (Martinez-Gimeno, et al., 2003) 
c.6974-6994del21bp frame-shift V2325fsX2329  (Martinez-Gimeno, et al., 2003) 
c.6893-6896delins7bp frame-shift L2298fsX2336  (Martinez-Gimeno, et al., 2003) 
c.6972-6977del6bpins11bp frame-shift 2325fsX2359 (Kondo, et al., 2003) 
c.6991delG frame-shift E2331fsX2358  (Sullivan, et al., 2006) 
IVS exon 41/ 42 junction 
IVS41-4G>A 
Splice site change  (Sullivan, et al., 2006) 
c.6961CAG>TAG Stop Q2321X (De Erkenez AC, 2002) 
c.7000T>A missense Y2334N new 
c.7006T>C frame-shift Stop2336fsX2377 (Martinez-Gimeno, et al., 2003) 
 
Nucleotide numbering reflects cDNA numbering with +1 corresponding to the A of the ATG translation initiation codon in the 
reference sequence (accession number NG_009118), according to journal guidelines (www.hgvs.org/mutnomen). The initiation 
codon is codon 1.   
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C.                      D.  
        
Figure 1. Fundus photography in the left eyes of A) Grandfather, B) father and C) son with the Y2334N mutation and D) the de 
novo case with H2309P, reveal characteristic bone-spicule pigmentation in the mid periphery. 
 
 
 
 
Figure 2. Fundus autoflourescence of the grandfather in 
the family segregating the Y2334N mutation, showing 
marked loss of RPE to within 10 degrees of fixation. 
 
Prognosis for Splicing Factor PRPF8-RP E1371 
 
 
 
 
 
 
 
Figure 3. OCT image of the left eye in the de novo H2309P mutation-carrying case, 
showing cystoid macula oedema 
 
 
Visual field loss to within 10 degrees of fixation was recorded in 23 of the 29 subjects for whom numeric data 
were available.  In most cases, loss of peripheral retina function or night blindness was first reported between the 
first and second decades. Statistical analysis was performed to determine whether there are significant differences 
between age of onset of disease in patients with different disease-causing mutations. Due to the limited 
information available and the small sample sizes of some of the mutation categories, this was only possible for 
three of the RP-causing mutations; H2309P, H2309R and R2310K.  The average age of onset of nyctalopia for 
each of these mutations is 6.6, 10.7 and 22 years respectively.  Statistical analysis showed significant differences 
between H2309P and R2310K (p=0.001), between H2309R and R2310K (p=0.02) and between H2309P and 
H2309R (p=0.026). This implies that patients carrying H2309P or H2309R mutations have a more severe 
phenotype, reflected by earlier onset of disease, than patients carrying the R2310K mutation.  
Acuity in the better eye was compared between the three most common mutations, all other PRPF8 mutations 
and with cumulated average data on generic RP obtained from the literature (Marmor 1980, Grover et al 1999) (see 
Table 4).  This suggests that the R2310K mutation is associated with relatively good acuity in all age ranges, by 
comparison with approximate figures for RP in general, but patients with the H2309P or H2309R mutations appear 
to have similar or worse visual loss than would be expected for combined RP. The scatterplot (Figure 4) suggests a 
trend towards worse acuity with increasing age for all published PRPF8 cases combined and for each of the three 
common mutations. However, the inclination of the trend for the combined data is not particularly steep, indicating 
that visual loss with PRPF8 mutations tends to be similar in late adulthood as it was at presentation. Comparison 
with combined RP figures suggest that the overall progression of PRPF8-RP is the same or slightly worse than 
expected for RP in general. However separate plots of the same measurements in cases with the three different 
mutations for which information is available again reveal that RP in patients with the H2309P or H2309R 
mutations progress more rapidly and have a poorer outcome than those with the R2310K mutation. 
CMO was reported in 11 of 75 subjects and posterior subcapsular cataract or other significant cataract was 
noted in 17 of 75 subjects. Both these figures are the minimum prevalence for these phenotypic variables as 
reporting is almost certainly incomplete.  
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Table 4. ETDRS letter score in the better seeing eye for the three most common and other PRPF8 mutations and 
comparison with cumulated average acuities from previous RP progression studies. 
 
 <20 years 20-39 years 30-59 years >60 years 
R2310K 92 (n=1) 75 (n=3)  75 (n=5) 
H2309P 56 (n=6) 65 (n=7)  47 (n=2) 
H2309R 75 (n=8) 51 (n=6) 60 (n=4) 0 (n=1) 
Others 60 (n=2) 70 (n=2) 43 (n=4) 40 (n=4) 
Combined RP 
Marmor 1980 75  60  
Combined RP Grover 
et al 1999   68 54 
 
 
 
 
 
 
 
Figure 4.  Graph comparing visual acuity in the better eye between the different PRPF8-causing mutations. 
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DISCUSSION 
The report of S2118F, R2310S and Y2334N mutations brings the total number of PRPF8-RP mutations to 
nineteen, accounting for approximately 1% of all RP cases. S2118F is the first PRPF8 mutation found outside 
exon 42, which has significant implications for future genetic screening in RP.  Nevertheless, these mutations are 
highly clustered at the C-terminus and are either missense changes or are nonsense mutations that change or delete 
at most only the last 37 amino-acids of this remarkably conserved 2335 amino acid protein. This pattern of 
mutations makes it likely that mutated PRPF8 protein will be present in patient cells, a theory supported by the 
observation that a PRPF8 mRNA containing one of the C-terminal frameshift mutations was not subject to 
nonsense mediated decay (Gamundi, et al., 2008). Furthermore, a mouse knock-in model with the H2309P PRPF8 
mutation exhibits sub-retinal pigment epithelium (RPE) deposits at two years of age (Graziotto et al 2010) but a 
PRPF8 knockout has no observable abnormalities (J.Graziotto, Q.Zhang and E.A.Pierce, unpublished).  These data 
are all consistent with the hypothesis that PRPF8-RP is the result of presence of abnormal protein.  However, in 
contrast, haploid yeast with H2387P, equivalent to the human H2309P mutation, have a growth sensitive 
phenotype, but the diploid heterozygous yeast grow completely normally (Boon, et al., 2007). This finding 
suggests that gene replacement therapy could still prove effective in this form of RP. 
The H2309P mutation has been reported previously in a large UK family (british1) and therefore when it was 
identified in another UK patient the initial expectation was that this individual was related to the original family. 
However, our analysis showed that it was in fact a de novo mutation. Such a finding is not unprecedented but is a 
relatively rare occurrence (Schwartz, et al., 2003). This observation could imply that this codon, and potentially 
this region of the gene, may in fact represent a mutation hotspot, rather than a domain essential to retinal function 
as previously proposed (McKie, et al., 2001).  The existence of such mutations also confirms that it is important 
for clinicians to consider the possibility of dominant disease even in isolated patients with RP, who are generally 
considered more likely to have recessive disease. 
Much of the published literature on PRPF8-RP (also known as RP13) concentrates on genetic analysis, with 
clinical findings often described only briefly and in limited detail. Four papers (Kondo, et al., 2003; Martinez-
Gimeno, et al., 2003; van Lith-Verhoeven, et al., 2002; Walia, et al., 2008) provide more detailed descriptions of 
the phenotype associated with individual mutations but give at best only a limited comparison with clinical 
findings in other families. Here we present clinical data on a family and two cases with new mutations, a de novo 
case of a known mutation, additional clinical data on two published families, and an overview of previously 
published clinical findings in eight further families. On the basis of these data, while dominantly inherited RP due 
to mutations in the PRPF8 gene can indeed be severe, overall prognosis for visual acuity is not as bleak as some 
previous reports have suggested.  Nyctalopia, visual field constriction and an abnormal or non-recordable ERG are 
consistent early findings. However, visual acuity in the better eye often remains normal or near-normal into 
middle-age. Furthermore Figure 4 shows only a modest overall trend towards a decline in vision with age, 
suggesting that this phenotype is not necessarily associated with profound or rapidly deteriorating visual loss. 
Comparison with acuity figures for progression of combined RP suggests that PRPF8-RP in general is similar or 
slightly worse than RP in general, but that at least one PRPF8 mutation, R2310K, gives rise to milder form of RP, 
while others are more severe. Some individuals with PRPF8-RP retain good visual acuity into the sixth or even 
seventh decade, and only 9 of the 64 cases for which acuity data are available have acuity in the better eye of 6/60 
or worse.  A similar range in severity has been documented for other forms of autosomal dominant RP (Jacobson, 
et al., 2000). 
The data most consistently available for patients, and which therefore allow comparison between patients with 
the different mutations, are age at onset of nyctalopia or visual field loss and visual acuity at a given age. We 
therefore compared these measurements in patients grouped according to the mutation they carried. This was only 
possible for the H2309P, H2309R and R2310K mutations, for which data were available on larger numbers of 
patients than the remaining mutations. Statistical analysis showed that H2309P conferred the earliest onset of night 
blindness and had the most severe prognosis for visual acuity, that H2309R mutation carriers have less severe 
symptoms and that R2310K carriers have the best outcome for these indicators.  
It is interesting to compare these findings with two recent studies performed in yeast (Boon, et al., 2007; 
Maeder, et al., 2009).  Both studies showed that the mutations which cause RP in human patients, when present in 
yeast Prp8 protein, result in its reduced association with the DEAD-box helicase Brr2p in the yeast nucleus (Boon, 
et al., 2007; Maeder, et al., 2009).  The association of Prp8p with Brr2p is thought to be essential for the 
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production of a mature spliceosome and yeast carrying the RP-causing mutations have reduced splicing activity.  
These studies also noted differences in the specific effects of the different RP-causing mutations.  Yeast Prp8p 
protein with mutations equivalent to H2309P and H2309R showed no association with Brr2p, while that carrying 
the R2310K-equivalent was still capable of interaction but at a reduced level.  Furthermore, haploid yeast with the 
RP-causing mutations show a temperature sensitive growth phenotype, with the yeast equivalents of H2309R and 
H2309P having more severe phenotypes than R2310K. It is therefore evident that the phenotype caused by these 
mutations in yeast, and their effect on interaction with Brr2, correlates with the severity of RP caused by their 
human equivalent mutations.  This correlation is tentative since information is only available for three of the 
nineteen mutations identified in human patients, and additional studies are required to determine whether other 
pathogenic mechanisms also contribute to clinical expression in patients with PRPF8 mutations. Nevertheless 
these observations provide suggestive evidence that human RP may be a consequence of defective splicing due to 
a mechanism similar to that observed by Boon and colleagues in yeast (Boon, et al., 2007). However, splicing 
deficiency studies in human cell lines have been equivocal. Several laboratories reported that splicing factor RP-
causing mutations caused measurable abnormalities in splicing in vitro (Ivings, et al., 2008; Mordes, et al., 2007; 
Wilkie, et al., 2008), but microarray analysis in vivo revealed no consistent splicing defects (Gamundi, et al., 2008; 
Rivolta, et al., 2006). Furthermore, the question as to why only the retina is affected in human patients remains 
unanswered.  
In summary, we report three new mutations and a de novo mutation in PRPF8, bringing the total number of RP-
causing mutations in this gene to nineteen. We have reviewed the RP phenotype associated with these mutations 
and find that, while the effect on peripheral retinal function is severe, patients generally retain good visual acuity 
in at least one eye until the fifth or sixth decade. We also find that patients with the H2309P or H2309R mutations 
have a worse prognosis than those with R2310K, and note that yeast lines carrying the equivalent mutations show 
the same severity trend for a temperature-sensitive growth phenotype and for interaction with Brr2, which may 
imply a common mechanism underlying the human and yeast phenotypes.  
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